Question 1

Can I use the PCE in patients older than 79 or younger than 40?

Accepted Answer

The equation is not validated outside the 40–79 age range. For younger adults, lifetime risk estimation or alternative tools such as QRISK may be used. For older adults, clinical judgement incorporating functional status and competing risks is advised.

Question 2

Does the PCE apply to non-American populations?

Accepted Answer

The PCE was derived from US cohorts and may not be perfectly calibrated in other regions. The WHO-ISH charts, QRISK (UK), or locally recalibrated versions should be preferred where available.

Question 3

Race is limited to Black or White — how do I classify other ethnic groups?

Accepted Answer

Current PCE guidance suggests using the White coefficients for all other race/ethnicity groups. This is a known limitation; risk-discussion thresholds may need adjustment for South Asian, East Asian, or Hispanic populations.

Question 4

Should I use the PCE for secondary prevention?

Accepted Answer

No. The PCE is designed for primary prevention. Patients with established ASCVD are high-risk and warrant intensive risk-factor management regardless of their PCE score.